相关实验视频

Updated: Jul 10, 2025

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

葛西他/纳布-帕克利塔塞尔与葛西他/卡博普拉丁治疗晚期泌尿腺癌

Xin An¹, Cong Xue¹, Meiting Chen¹

¹Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.

BJU international

|November 27, 2023

概括

第一线纳米颗粒与白素结合 (nab) - - 帕克利塔塞尔加上凝胺 (GA) 显示出与卡博普拉丁加上凝胺 (GCb) 在西斯普拉丁不合格的转移性尿路细胞癌 (mUC) 中具有可比的疗效. 该GA疗法提供了更好的耐受性,建议它作为一个可行的替代治疗选择.

科学领域:

在瘤学瘤学.
临床试验临床试验
尿癌研究尿癌研究

背景情况:

转移性尿路细胞癌 (mUC) 构成了重大挑战,特别是对于那些无法接受基于西斯的化疗的患者来说.
这种患者群体的第一线治疗选择需要仔细评估疗效和安全性.

研究的目的:

为了比较纳米颗粒与素结合 (nab) - 帕克利塔塞尔加上凝胺 (GA) 与卡博普拉丁加上凝胺 (GCb) 的疗效和安全性,在mUC的西斯普拉丁不合格患者中.
评估两种治疗方案的无进展生存率 (PFS),总生存率 (OS),客观反应率 (ORR),疾病控制率 (DCR) 和安全概况.

主要方法:

一项III期随机试验,对未接受过治疗的,不符合cisplatin的mUC患者进行GA或GCb手臂.
主要终点是PFS,次要终点包括OS,ORR,DCR,安全性和患者报告的结果 (PRO).
该试验因患者积累缓慢而提前终止.

主要成果:

平均PFS为GA的6.7个月,与GCb的5.9个月相比 (P=0.248);平均OS为GA的12.1个月,与GCb的10.7个月相比 (P=0.837).
对GA的ORR为40%,对GCb为46.4% (P=0.637),对GA的DCR为72%,对GCb为68% (P=0.188).这两种情况的相对比率是相同的.
GA组的血小板减少了3-4级的血小板减少,剂量减少/延迟减少了,外围感官神经病变更高,但可以控制.

结论:

虽然没有为最终比较提供动力,但第一线GA在本研究中显示出与GCb相似的疗效.
纳布 - 帕克利塔克塞尔加上吉姆西塔宾治疗方案表现出更好的耐受性,并可能代表卡博普拉丁加上吉姆西塔宾的合理替代方案,用于西斯普拉丁不符合条件的mUC患者.

关键词:

卡博普拉丁是碳酸盐中的一种.西斯-不符合条件第一线的第一线.这种药物是 gemcitabine.转移性尿路细胞癌癌.纳布-帕克利塔克塞尔 (NAB-paclitaxel) 是一种药物.

更多相关视频

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...